Bristol Wins First Of Two Important Opdivo/Yervoy First-Line NSCLC Approvals
Executive Summary
Data from CheckMate-9LA and -227 that will be presented at the ASCO virtual meeting support a low-dose chemo combo with the two drugs and the newly US FDA-approved chemo-free indication.
You may also be interested in...
Latecomer Libtayo Wins Coveted First-Line NSCLC Monotherapy Indication
Sanofi/Regeneron's PD-1 inhibitor Libtayo joins Keytruda and Tecentriq as the only PD-1/L1s approved by the US FDA as monotherapy for first-line non-small cell lung cancer.
Merck’s Keytruda Works With Lenvima In Renal Cancer, But Not With Yervoy In Lung Cancer
Merck’s PD-1 inhibitor combined with Lenvima offered benefit in RCC, but use with Bristol’s Yervoy in metastatic NSCLC showed no benefit compared to Keytruda monotherapy.
Bristol Highlights Growth Is Not Coming From Opdivo Alone
Recent launches and products acquired with Celgene are helping BMS grow, CEO Caforio said, while Opdivo is moving toward resuming growth thanks to first-line NSCLC and other factors.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports